←
Simon Stern1,753 posts
Simon Stern avatar

Simon Stern

@DrSStern

Consultant Haematologist. Interested in haemato-oncology in general and multiple myeloma in particular.

◷ Joined March 2015▧ 72 Photos and videos
Simon Stern avatar
Simon Stern@DrSStern·Oct 11

Latest results from @iStopMM show that screening for MGUS decreases the diagnostic delay for myeloma requiring treatment by a year. Longer follow-up is required to show any survival benefit. Journal of Clinical Oncology ascopubs.org/doi/full/10.120…

Rahul Banerjee, MD, FACP avatar
⟳ Simon Stern retweeted
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·Oct 1

My #IMS26 Top 5 myeloma abstracts: 1️⃣ CARTITUDE-2 A: 50% CAR-T cure fraction 2️⃣ PERSEUS: 6-yr PFS 🤩, but HR need better 3️⃣ MajesTEC-3: 86% functional cure with BsAb/dara? 4️⃣ EXCALIBER-RRMM: CELMODs & MRD approvals! 5️⃣ CERVINO: Q4W is in, CRS is out 👋🏽 cancertherapyadvisor.com/fea…

Post attachment
Pablo Tenorio Feixas avatar
⟳ Simon Stern retweeted
Pablo Tenorio Feixas@ptenfei·Sep 25

#IMS26: Dr Sina Beer shares data from MUKnine/OPTIMUM, challenging how we define (and treat) ultra-high-risk myeloma. Key lessons: - Intensified, risk-adapted treatment improves outcomes. - SKY92 gene-expression profiling identifies high-risk patients missed by DNA-based criteria. - Combine IMS-IMWG HRCA + SKY93 testing could help with treatment selection. Better knowledge of disease biology → better risk stratification → better outcomes! Fascinating talk, congratulations Sina, @MyMKaiser and rest of colleagues! @Myeloma_Society

Post attachmentPost attachmentPost attachment
Vincent Rajkumar avatar
⟳ Simon Stern retweeted
Vincent Rajkumar@VincentRK·Sep 25

We have a cure definition for myeloma. Requires: 1) Off all therapy and sustained MRD negative for 5 years 2) Negative imaging studies Presented by @NikhilMunshiMD #IMS26 @Myeloma_Society Note: 1) We need to see how this definition performs. Relapse rate for patients meeting these cure criteria must ideally be less than 5%. If not, we may have to adjust the criteria. 2) I hope the cure criteria will be the impetus to stop doing trials with endless therapy. You cannot claim cure with continuous therapy. I’m glad the field is mostly aligned on this. Cure for patients and public in any disease has a deep meaning. Cure means cure. We cannot dilute it.

Martyn Ziegler avatar
⟳ Simon Stern retweeted
Martyn Ziegler@martynziegler·Sep 25

Oasis at Knebworth 1996: shortly after Man City relegated to the Championship. Oasis at Knebworth 2027: .....??? Whatever

Simon Stern avatar
Simon Stern@DrSStern·Sep 25

OK, so AI might be threatening to wipe out humanity, but before it does that it looks like it could be used to predict progression in smouldering myeloma. Really interesting presentation by @aksimhal from MSK at #IMS2026

Post attachment
Raj Chakraborty avatar
⟳ Simon Stern retweeted
Raj Chakraborty@rajshekharucms·Sep 24

Incredible 2-year PFS with Ramantamig in a ~95% CD38-refractory and 100% triple-class exposed population! These results are substantially superior compared to single-agent BCMA BsAbs and BCMA or GPRC5D CAR Ts in similar population. Based on these results, its plausible that we will see a near-flat PFS curve with Ram in Trilogy-5! #IMS26 @AlGarfall @MileHighMyeloma

Post attachment
Rahul Banerjee, MD, FACP avatar
⟳ Simon Stern retweeted
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·Sep 24

#IMS26 Elegant (post hoc) MajesTEC-3 analysis by @End_myeloma Unlike other myeloma drugs, I bet real-world tec-dara OS will look *better* than MajesTEC-3 did. Why? Because we now know PPx toci, PPx IVIG, etc - early BsAb deaths can be prevented, vs fatal PD with Dara-Pd can't.

Post attachment
Vincent Rajkumar avatar
⟳ Simon Stern retweeted
Vincent Rajkumar@VincentRK·Sep 20

Three things I recommend for using Bispecific antibodies in myeloma: 1) Prophylactic tocilizumab with first dose 2) Monthly IVIG regardless of the IgG level 3) Consider reducing frequency/stopping after excellent response. This applies to all the approved bispecifics: teclistamab, elranatamab, linvoseltamab, and talquetamab. Academic centers with expertise and close monitoring capabilities may skip the prophylactic tocilizumab but in general I do not see community adoption without it. The data on routine IVIG and early use before the IgG levels drop or infections occur is good and sufficient to move forward. It’s recommended in NCCN and mSMART. Bispecifics are better at controlling myeloma than standard triplets and quads, but pose a much higher risk of serious life threatening infections without prophylaxis and careful adjustment of dosing schedule based on response and patient characteristics. #IMS26

Vincent Rajkumar avatar
⟳ Simon Stern retweeted
Vincent Rajkumar@VincentRK·Sep 4

Profound sorry that my mentor, friend, and colleague, the legend Bob Kyle passed away. His contributions to patients, medicine, myeloma, @IMFmyeloma @MayoClinic myeloma group, and the institution are monumental. A role model who will be remembered for his integrity and commitment to patients. I owe my career to him. He leaves behind a legacy of experts at Mayo Clinic as well as world over who were influenced greatly by him. See thread for links to a video an article on him that I wrote for @MayoProceedings Post your memories below.

Post attachment
Mahmoud Gaballa avatar
⟳ Simon Stern retweeted
Mahmoud Gaballa@mahrefat·Aug 31

Our work on bispecifics in plasma cell leukemia is now published. Talquetamab showed markedly better outcomes than BCMA bispecifics in patients with active PCL (≥5% circulating PCs), including those who were BCMA-naive. With virtually no prospective trial data in this space, this striking signal may help inform treatment choice. authors.elsevier.com/sd/arti… #mmsm @DrKrinaPatel @MDAndersonnews @MyelomaSLC @RahulBanerjeeMD @Transplant_Doc

Post attachment
Breno Moreno de Gusmão avatar
⟳ Simon Stern retweeted
Breno Moreno de Gusmão@morenodegusmao·Aug 25

Final MAIA analysis: D-Rd reached median OS of 90.3 months (HR 0.67 vs. Rd) after 89.3 months of follow-up in transplant-ineligible NDMM. A tough number to beat - will quadruplet regimens have to work hard to surpass it? doi.org/10.1038/s41375-026-0… #MM #mmsm